Cart
sales@molnova.com
EX-229
CAS No. 1219739-36-2
EX-229( EX 229 | EX229 )
Catalog No. M10829 CAS No. 1219739-36-2
A small molecule AMPK activator that dose-dependently increases AMPK activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 73 | In Stock |
|
| 2MG | 42 | In Stock |
|
| 5MG | 65 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 221 | In Stock |
|
| 50MG | 368 | In Stock |
|
| 100MG | 553 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEX-229
-
NoteResearch use only, not for human use.
-
Brief DescriptionA small molecule AMPK activator that dose-dependently increases AMPK activity.
-
DescriptionA small molecule AMPK activator that dose-dependently increases AMPK activity of α1-, α2-, β1- and β2-containing complexes at 50 uM; induces AMPK activation and glucose uptak in a wortmannin-independent manner; increases fatty acid oxidation in L6 myotubes.
-
In Vitro——
-
In Vivo——
-
SynonymsEX 229 | EX229
-
PathwayMembrane Transporter/Ion Channel
-
TargetAMPK
-
RecptorAMPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1219739-36-2
-
Formula Weight431.876
-
Molecular FormulaC24H18ClN3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : 5.4 mg/mL12.50 mM
-
SMILESO=C(O)C1=CC(OC2=NC3=CC(C4=CC5=C(N(C)C=C5)C=C4)=C(Cl)C=C3N2)=CC=C1C
-
Chemical Name5-{[6-chloro-5-(1-methylindol-5-yl)-1H-benzimidazol-2-yl]oxy}-2-methyl-benzoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lai YC, et al. Biochem J. 2014 Jun 15;460(3):363-75.
2. Bultot L, et al. Am J Physiol Endocrinol Metab. 2016 Oct 1;311(4):E706-E719.
3. Patent WO2010036613, EX229.
molnova catalog
related products
-
Dorsomorphin
Dorsomorphin (BML-275, Compound C) is a potent, selective and reversible AMPK inhibitor with Ki of 109 nM.
-
ZLN-024
A novel AMPK allosteric activator that has no effect on mitochondrial function or the ADP/ATP ratio; directly activate recombinant AMPK α1β1γ1 and its homologue α2β1γ1 with EC50 of 0.42 uM and 0.95 uM, respectively.
-
Aldometanib
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor that prevents FBP from binding to v-ATPase-associated aldolase and activates lysosomal AMPK, useful in metabolic homeostasis research .
